Merck KGaA moves to block Schering acquisition

Merck KGaA is rapidly building up a 25 percent stake in Schering in order to block Bayer's €86 million takeover bid for the company, according to a report by AFX. Bayer's bid is conditional on a 75 percent acceptance rate by Wednesday. AFX reports that Merck KGaA is expected to announce it has acquired more than 25 percent of Schering's stock soon.

- read the AFX report for more

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.